Clinical trials

  • ENCORAFENIB for Metastatic colorectal cancer | BRAF V600E mutation positive
  • (S)-2,2',2''-(10-(2-(4-(3-((4-(2-(2-CYANO-4,4-DIFLUOROPYRROLIDIN-1-YL)-2-OXOETHYLCARBAMOYL)-QUINOLIN-6-YL)(METHYL)AMINO)-PROPYL)PIPERAZIN-1-YL)-2-OXOETHYL)-68GA-[1,4,7,10]-TETRAAZACYCLODODECANE-1,4,7-TRIYL)TRIACETATE for Ductal carcinoma in situ | Breast cancer
  • LB-208 for Solid tumor | Lymphoma
  • ZIMBERELIMAB for Non-small cell lung cancer | Metastatic non-small cell lung cancer
  • (2R,3R,11BR)-1,3,4,6,7,11B-HEXAHYDRO-9,10-DIMETHOXY-3-(2-METHYLPROPYL)-2H-BENZO[A]QUINOLIZIN-2-OL for Tardive dyskinesia
  • TULISOKIBART for Systemic sclerosis associated with interstitial lung disease
  • AUTOGENE CEVUMERAN for Colorectal cancer (resected, Stage II high-risk and Stage III)
  • CLONAZEPAM for Burning mouth syndrome
  • RIBOCICLIB for Advanced hormone receptor-positive (HR+) breast cancer
  • CART45RA-NKG2D CELLS for B-cell acute lymphoblastic leukemia (relapsed/refractory) | T-cell acute lymphoblastic leukemia (relapsed/refractory)
  • MOSUNETUZUMAB for Follicular lymphoma
  • ELVN-002-1 for HER2-positive solid tumours | Colorectal adenocarcinoma | Breast cancer